New drug cocktail aims to boost remission in rare blood cancer
NCT ID NCT04263480
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding carfilzomib to ibrutinib improves outcomes for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher rates of very good partial or complete remission after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carfilzomib and Ibrutinib
What this could lead to
If successful, this combination could offer a more effective chemotherapy-free option for Waldenström's macroglobulinemia, especially for patients with certain genetic profiles.
What could go wrong
This is a Phase 2 trial with 99 participants, so results are preliminary. The combination may not prove significantly better than ibrutinib alone, and side effects from adding carfilzomib could be higher.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexandra Hospital
Athens, 11528, Greece
-
Bruederkrankenhaus St. Josef
Paderborn, 33098, Germany
-
Ev. Diakoniekrankenhaus
Bremen, 28239, Germany
-
Gemeinschaftspraxis Mohm / Prange-Krex
Dresden, 01307, Germany
-
Hämatologie/Onkologie München Pasing MVZ GmbH
Munich, 81241, Germany
-
Hämatologisch-Onkologische Schwerpunktpraxis Drs. Schöttker & Pretscher
Würzburg, 97080, Germany
-
Kath. St.-Johannes-Gesellschaft Dortmund gGmbH
Dortmund, 44137, Germany
-
Kliniken Ostalb, Staufenklinikum Schw. Gmuend
Mutlangen, 72557, Germany
-
MediProject Onkologisches Ambulanzzentrum Hannover
Hanover, 30171, Germany
-
Medizinische Universität Wien
Vienna, 1090, Austria
-
OncoResearch Lerchenfeld GmbH
Hamburg, 22081, Germany
-
Praxis Dr. Vehling-Kaiser
Landshut, 84130, Germany
-
Praxis für Hämatologie und Onkologie, onkologische Tagesklinik-VK&K Studien GbR
Landshut, 84036, Germany
-
Uniklinikum Salzburg
Salzburg, 5020, Austria
-
University Hospital Ulm
Ulm, 89081, Germany
-
Universitätsmedizin Rostock
Rostock, 18055, Germany
-
Vivantes Klinikum am Urban
Berlin, 10967, Germany